{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:13:48Z","timestamp":1788250428503,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dld.2025.12.019","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:10:08Z","timestamp":1768479008000},"page":"384-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: The PRODIGE 85-FFCD 1804-KANALRAD trial"],"prefix":"10.1016","volume":"58","author":[{"given":"Sophia","family":"Medjahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-7119","authenticated-orcid":false,"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-8525","authenticated-orcid":false,"given":"Karine Le","family":"Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5209-3558","authenticated-orcid":false,"given":"Nicolas","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Naessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Frulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-4616","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.12.019_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6603175","article-title":"Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975\u20132002","volume":"5","author":"Brewster","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2025.12.019_bib0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/DCR.0b013e31819eb7f0","article-title":"Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base","volume":"52","author":"Bilimoria","year":"2009","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"10.1016\/j.dld.2025.12.019_bib0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.dld.2025.12.019_bib0004","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Cancer de l\u2019anus: recommandations de pratique clinique de l\u2019Intergroupe fran\u00e7ais pour le diagnostic, le traitement et le suivi","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1016\/j.dld.2025.12.019_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.12.019_bib0006","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.canrad.2016.07.061","article-title":"Radioth\u00e9rapie des cancers du canal anal","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer\/Radioth\u00e9rapie"},{"issue":"1","key":"10.1016\/j.dld.2025.12.019_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted IMRT with 5-FU and mitomycin-C in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.dld.2025.12.019_bib0008","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","year":"1996","journal-title":"Lancet."},{"key":"10.1016\/j.dld.2025.12.019_bib0009","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in locally advanced anal cancer: EORTC trial","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dld.2025.12.019_bib0010","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2010.07.1995","article-title":"Mind the gap\u201d: impact of treatment gap and overall time in the first UK Anal Cancer trial (ACT I)","volume":"81","author":"Glynne-Jones","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.dld.2025.12.019_bib0011","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification in locally advanced anal canal carcinoma: UNICANCER ACCORD 03 final analysis","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.dld.2025.12.019_bib0012","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.dld.2025.12.019_bib0013","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable anal squamous cell carcinoma (Epitopes-HPV02)","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2025.12.019_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from Epitopes-HPV01 and HPV02 studies in advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dld.2025.12.019_bib0015","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"InterAAct: randomized phase II trial of cisplatin\/5-FU vs carboplatin\/paclitaxel in advanced anal cancer","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.12.019_bib0016","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1016\/j.ijrobp.2016.06.1006","article-title":"Development of the PLATO umbrella trial for radiation dose questions in anal SCC","volume":"96","author":"Sebag-Montefiore","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.dld.2025.12.019_bib0017","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified DCF as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60)","volume":"25","author":"Kim","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.dld.2025.12.019_bib0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1748-717X-5-10","article-title":"FDG-PET\/CT for staging and target volume delineation in anal carcinoma","volume":"5","author":"Krengli","year":"2010","journal-title":"Radiat Oncol"},{"issue":"15","key":"10.1016\/j.dld.2025.12.019_bib0019","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"IMRT versus conventional radiation therapy for anal canal SCC","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.dld.2025.12.019_bib0020","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in anal SCC: post hoc ACT II analysis","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.dld.2025.12.019_bib0021","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.3390\/ijms21186838","article-title":"Anti-telomerase CD4+ Th1 immunity and MDSCs in DCF-treated advanced anal SCC","volume":"21","author":"Spehner","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.dld.2025.12.019_bib0022","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: ancillary epitopes-HPV02 study","volume":"25","author":"Bernard-Tessier","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2025.12.019_bib0023","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal SCC","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825012587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825012587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:23:56Z","timestamp":1773984236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825012587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1590865825012587"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.12.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: The PRODIGE 85-FFCD 1804-KANALRAD trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}